OTC · Drug Manufacturers - Specialty & Generic

Shield Therapeutics plc (SHIEF) Stock

$0.06 -10.22% OTC: SHIEF Healthcare

Shield Therapeutics plc operates as a specialized pharmaceutical firm, dedicated to developing and bringing to market advanced clinical therapies that address significant unfulfilled medical requirements. Its flagship product, Accrufer/Feraccru, offers an innovative, non-salt-based oral treatment specifically for adults suffering from iron deficiency, irrespective of whether anemia is present.

Valuation

MetricValue
Price$0.06
Market Cap$62.03M
P/E Ratio-3.05
P/B Ratio-3.74
P/S Ratio1.11
EPS (TTM)$-0.02
52-Week High$0.17
52-Week Low$0.04
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE121.87%
ROA-27.96%
ROCE-69.31%
Gross Margin44.16%
Operating Margin-20.44%
Net Margin-35.72%
Debt/Equity-2.00
Current Ratio0.90

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.0M$5.0M$17.0M$40.0M$51.0M
Operating Profit$-20.0M$-26.0M$-40.0M$-29.0M$-10.0M
Net Profit$-20.0M$-50.0M$-42.0M$-34.0M$-18.0M
EPS$-0.09$-0.21$-0.06$-0.04$-0.02
Op Margin-1336.0%-572.0%-239.4%-71.1%-20.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$44.0M$22.0M$49.0M$57.0M$65.0M
Total Liabilities$3.0M$17.0M$34.0M$59.0M$80.0M
Cash$12.0M$3.0M$18.0M$7.0M$12.0M
Borrowings$0$6.0M$26.0M$26.0M$30.0M

Latest News

Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty PR Newswire · Jul 9, 2026 Shield Therapeutics plc's (LON:STX) Path To Profitability Simply Wall St. · Jun 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-17.0M$-18.0M$-38.0M$-7.0M$-9.0M
Investing Cash Flow$-4.0M$-4.0M$-3.0M$-5.0M$0
Financing Cash Flow$-10.0M$-2.0M$-15.0M$-3.0M$0
Net Cash Flow$9.0M$-11.0M$11.0M$-7.0M$5.0M
Free Cash Flow$-19.0M$-20.0M$-38.0M$-9.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.03
EV / EBITDA-8.22
FCF Yield-33.81%
Quick Ratio0.72
Interest Coverage-1.36
Return 1Y50.65%
Return 3Y-53.60%
Return 5Y—

Ownership

Insiders Held61.75%
Institutions Held3.34%
Institutions Float Held8.72%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BIOYFBioSyent Inc. $10.50 +0.41% 18.10 $120.04M 1.52%
GGBXFGreen Growth Brands Inc. $0.00 — 0.00 $2061 0.00%
GRUSFGrown Rogue International Inc. $0.41 +2.68% -123.21 $102.47M 0.00%
HLTRFHLS Therapeutics Inc. $2.98 +0.00% -9.24 $93.20M 0.00%
JUSHFJushi Holdings Inc. $0.41 +7.23% -1.23 $82.43M 0.00%

About Shield Therapeutics plc

Shield Therapeutics plc operates as a specialized pharmaceutical firm, dedicated to developing and bringing to market advanced clinical therapies that address significant unfulfilled medical requirements. Its flagship product, Accrufer/Feraccru, offers an innovative, non-salt-based oral treatment specifically for adults suffering from iron deficiency, irrespective of whether anemia is present. Furthermore, the company is advancing PT20, a pioneering iron-based phosphate binder that has successfully concluded its pivotal Phase II trials for managing hyperphosphatemia in individuals with chronic kidney disease. This enterprise was founded in 2008 and maintains its headquarters in Gateshead, United Kingdom.

Shield Therapeutics plc is headquartered in GB.

Shield Therapeutics plc (SHIEF) stock trades at $0.06 with a market capitalization of $62.03M. The stock is valued at a price-to-earnings (P/E) ratio of -3.05, price-to-book of -3.74, price-to-sales of 1.11. Over the past 52 weeks the stock has ranged between $0.04 and $0.17, and currently trades 64.7% below its 52-week high.

On profitability, Shield Therapeutics plc generates a return on equity (ROE) of 121.87% — well above the market average, a sign of a high-quality business, return on capital employed of -69.31%, an operating margin of -20.44%, a net profit margin of -35.72%.

Official website: www.shieldtherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides